A side by side comparison..., page-27

Moon? Nup…. Try Nebula.

I recall Paul being asked the question about the lower dose in stage 1 of the phase 3 trial in a webinar.

It seems the team are sure the twice weekly dose at 1.5mg delivers a very similar therapeutic effect as the 2mg dose based off internal studies. Therefore delivering a minimal effective dose at 25% less product.

One other insight from the trial design, we may get more safety and efficacy data to digest (this time as a phase 3 trial) when the time reports on stage 1 of the phase 3, even if the trial proceeds without modification.

The look through is the 1.5mg twice weekly (if chosen) is safe and EFFECTIVE in a phase 3 TRIAL!

many catalysts emerging crew!